Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall ...

Unless you’ve been living under a rock, you know that weight-loss drugs are the talk of the town. GLP-1 drugs, in particular, ...

Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs market. Merck on Dec. 16 said it had just ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Weight Watchers va-t-il survivre à la révolution des médicaments coupe-faim ? En France, WW va se délester de tous ses ...

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...

Here are the stocks that have reflected the key market trends of 2024 and have been closely watched by investors.

Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...

During Q3 2024, the Lazard International Strategic Equity Portfolio rose 5.5% (net), lagging the MSCI EAFE Index. Click here ...

Biden officials recently proposed allowing Medicare to start covering GLP-1 medications to treat obesity. It's unclear ...

CommonSpirit Health said the agreement with Humana to provide services in Colorado for Medicare Advantage patients will ...